Stock Code: 1215



CHAROEN POKPHAND ENTERPRISE (TAIWAN) CO., LTD.

2024 Annual General Shareholders' Meeting

Meeting Handbook

June 25, 2024

Table of Contents

I. 2024 Annual General Shareholders' Meeting Agenda	1
II. Attachment	
Attachment 1: 2023 Business Report	7
Attachment 2: Audit Committee's Review Report	8
Attachment 3: 2023 Parent Company Only Financial Statements and Report of Independent Accountants	9
Attachment 4: 2023 Consolidated Financial Statements and Report of Independent Accountants	8
Attachment 5: Table of 2023 Distribution of Surplus Earnings2	8
III. Appendix	
Rules of Procedure for Shareholders Meetings2	9
Articles of Incorporation 3	1
Current Shareholding of All Directors 3	6

CHAROEN POKPHAND ENTERPRISE (TAIWAN) CO., LTD.

2024 Annual General Shareholders' Meeting

Agenda

- I. Means of Meeting Convention: Physical shareholders meeting.
- II. Time: 10:00 a.m., Thursday, June 25, 2024
- III. Location : Conference Room at Nantou plant of the Company No. 17, Gongye E. Rd., Nangang Industrial Park, Nantou City, Nantou County, Taiwan
- IV. Meeting Procedures
 - 1. Call the Meeting to Order
 - 2. Chairman Takes Chair
 - 3. Chairman Remarks
 - 4. Management Reports
 - (1) 2023 Business Report.
 - (2) Audit Committee's Review Report on the 2023 Financial Statements and Records.
 - (3) Report of Distribution of 2023 Employees' Compensation.
 - (4) Report of Distribution of 2023 Cash Dividends.
 - 5. Proposals
 - (1) Adoption of the 2023 Business Report and Financial Statements.
 - (2) Adoption of the Proposal for 2023 Distribution of Surplus Earnings.
 - 6. Discussion
 - (1) Discussion to approve the lifting of non-competition restrictions for directors and independent directors of the Company.
 - 7. Questions and Motions
 - 8. Meeting Adjournment

Management Reports

- 1.2023 Business Report (Please refer to page 8, Attachment 1)
- 2. Audit Committee's Review Report on the 2023 Financial Statements and Records (Please refer to page 9, Attachment 2)
- 3. Report of Distribution of 2023 Employees' Compensation
- (1) In accordance with Article 29-1 of the Company's Articles of Incorporation, employees' compensation shall be distributed at least 1% of profits of the current year.
- (2) The 2023 employees' compensation is NT\$28,564,500 which was approved by the meeting of the Board of Directors on May 6, 2024, and totally distributed in cash.
- 4. Report of Distribution of 2023 Cash Dividends
- (1) In accordance with Article 29 of the Company's Articles of Incorporation, when the distributable dividends is paid in cash, the proposal shall be resolved by a majority vote at a meeting of the Board of Directors attended by two-thirds of the total number of directors of the Company, and reported to the Annual General Shareholders' Meeting.
- (2) The 2023 Cash Dividends is at NT\$ 5.5 per share, amounting to NT\$ 1,621,345,539 in total which was resolved by the meeting of the Board of Directors on May 6, 2024. The cash dividend distribution will be rounded down to the nearest NT dollar and the sum of the cash dividend with a value less than NT\$1 will be recognized as the Company's other income.
- (3) The Proposal has been resolved by the Board of Directors and set up the ex-dividend record date on July. 2, 2024 and payment date on July. 19, 2024 for the shareholders' cash dividend. If the proposed dividend distribution rate is affected by the number of outstanding shares due to the buyback of shares or other reasons, the Chairman is authorized to adjust the changes.

Proposals

Item 1 Proposed by the Board

Proposal: Adoption of the 2023 Business Report and Financial Statements.

Explanation:

- 1. CPE's 2023 Financial Statements, including the Balance Sheets, Statements of Comprehensive Income, Statements of Changes in Equity, and Statements of Cash Flows, were audited by independent auditors. Such Financial Statements together with Business Report had been resolved by the Board of Directors and reviewed by the Audit Committee.
- 2. The aforementioned report and statements are attached hereto as page 7~27, Attachments 1, 3 and 4. Please ratify.

Resolution:

Item 2 Proposed by the Board

Proposal: Adoption of the Proposal for 2023 Distribution of Surplus Earnings.

Explanation:

Table of 2023 Distribution of Surplus Earnings was prepared in accordance with Article 29 of the Company's Articles of Incorporation, and had been resolved by the Board of Directors and reviewed by the Audit Committee. The aforementioned Table is attached hereto as page 28, Attachments 5. Please ratify.

Resolution:

Discussion

Item 1 Proposed by the Board

Proposal: Discussion to approve the lifting of non-competition restrictions for directors and independent directors of the Company.

Explanation:

- 1. Pursuant to Article 209 of the Company Act, "A director who does anything for himself or on behalf of another person that is within the scope of the company's business, shall explain to the meeting of shareholders the essential contents of such an act and secure its approval."
- 2. Based on business and investment purposes, the Company hereby proposes to lift the non-competition restrictions on the current directors (including independent directors).
- 3. Details of the Duties Subject to Releasing the Directors and Independent Directors from Non-competition, please refer as follows:

CHAROEN POKPHAND ENTERPRISE (TAIWAN) CO., LTD.

Names and position titles of directors and independent directors whose non-compete behavior has been lifted

Position title	Name	Currently holding positions in other companies
Chairman	Wu Yeh Cheng	 Director of Plenty Type Limited (Cayman Islands) Director of Charoen Pokphand (Taiwan) Corp., Ltd. Supervisor of Arbor Acres (Taiwan) Co., Ltd.
Director	Prasert Poongkumarn	None.
Director	Chu Hsiung Lin	 Chairman of Arbor Acres (Taiwan) Co., Ltd. Chairman of Charoen Pokphand (Taiwan) Corp., Ltd. Director of Plenty Type Limited (Cayman Islands)
Director	Thong Chotirat	 Director of Arbor Acres (Taiwan) Co., Ltd. Director of Charoen Pokphand (Taiwan) Corp., Ltd.
Director	Monchai Leelaharat	 Director of Plenty Type Limited (Cayman Islands) Director of Rui Mu Foods Co., Ltd. Director of Rui Fu Foods Co., Ltd. Director of Perfect Companion (Taiwan) Co., Ltd. Director of Sheng Da Foods Co., Ltd. Supervisor of Charoen Pokphand (Taiwan) Corp. Ltd. Supervisor of Feng Sheng Livestock Co., Ltd. Chairman of Ta Chung Investment Co., Ltd. Chairman of Chun Ta Investment Co., Ltd.
Independent Director	Yen Sung Li	 Independent Director of Chicony Electronics Co.,Ltd. Independent Director of Sincere Navigation Corporation Independent Director of Taiwan FamilyMart Co.,Ltd.
Independent Director	Tsu M. Ongg	 Head of Habitech Architects Director of Career Consulting Co., Ltd. Supervisor of Fubon Real Estate Management
Independent Director	Jin-Shong Yang	None.

Resolution:

Questions and Motions

Meeting Adjournment

CHAROEN POKPHAND ENTERPRISE (TAIWAN) CO., LTD.

2023 Business Report

1. Operating Principles

For a long time, we have been dedicated to the agriculture, livestock, and food core business. We aggressively established a business model to integrate upper, middle, and lower stream of the industry, including feed manufacturing, livestock breeding, electric slaughtering, fresh frozen meat, meat processing food, egg products, etc. In addition, implementing our marketing strategies of brands enhancement, intensive physical e-commerce channels, procurement and R&D strategies, and also the most rigorous quality control operation, we insist on a fully control of quality and completed traceability from raw material supply chain management, processing, warehousing to products delivering in order to ensure the food safety. Our consistent business philosophy is to provide consumers with high-quality meat which is safe, hygienic, convenient, healthy, and highly qualified with reasonable price.

2. Implementation Overview

In 2023, the Company has shown progress on various business indicators compared with the previous years, including production and marketing cost control, breeding management, livestock breeding rates, breeder egg production rates, brand management, physical marketing channels, strengthened R&D and production of food processing, e-commerce channel development, etc. Thanks to the efforts of all colleagues, the Company still had an operating performance of EPS NT\$ 7.70.

3. Operating Performance

According to the Company's 2023 Parent Company Only Financial Statements, the operating revenue was NT\$27,235,093 thousands, the operating profit was NT\$2,938,887 thousands, the profit before income tax was NT\$2,827,280 thousands, and the earnings per share before income tax was NT\$9.59.

4. Budget Implementation

In accordance with the "Regulations Governing the Publication of Financial Forecast of Public Companies", the Company does not have to prepare financial forecasts to the public in 2023. However, the overall business performance is better than the company's internal operating plan.

5. Profitability Analysis (Based on the Company's 2023 Parent Company Only Financial Statements)

Return on total assets	10.00%
Return on owners' Equity	24.20%
Ratio of profit before income tax to paid-in capital	95.91%
Profit margin	8.33%
Earnings Per Share	NT\$ 7.70

6. Research and Development

- (1) Develop a variety of Chinese-style and exotic cuisines, and western sausage and egg products, such as thirteen spice powder chicken breast, shredded pork and golden egg fried rice, Thai tossed pork rice, French truffle risotto, black truffle mushroom pasta, and smoked truffle Cheese sausage, green peppercorns and tiger-patterned eggs, steamed egg chicken white soup, etc., for consumers to enjoy delicious meal anytime anywhere in a more convenient and simple way.
- (2) Targeting the needs and trends for high-protein diets, further develop more flavored chicken breast salad products, such as, such as Japanese curry salad breasts, green peppercorn tender chicken breasts, light spicy salad breasts, black pepper garlic chicken fillet, Mexican chicken fillet and other products, and expand the sales market share of each channel.

Chairman: Wu Yeh, Cheng CEO: Thong Chotirat Chief Accountant: Su Hua Lee

CHAROEN POKPHAND ENTERPRISE (TAIWAN) CO., LTD.

Audit Committee's Review Report

The Board of Directors has submitted the Company's Business Report, Financial Statements and

Proposal for Distribution of Surplus Earnings for the year 2023 to Audit Committee. The CPA firm of

PricewaterhouseCoopers, Taiwan had audited the Financial Statements and issued the Audit Report. The

aforementioned Business Report, Financial Statements and Proposal for Distribution of Surplus Earnings had

been reviewed by the Audit Committee and deemed that it is complied with the Company Act, related laws

and regulations. In accordance with the Article 14-4 of the Securities and Exchange Act and the Article 219

of the Company Act, we hereby submit the report.

To:

The 2024 Annual General Shareholders' Meeting of the Company

CHAROEN POKPHAND ENTERPRISE (TAIWAN) CO., LTD.

Convener of Audit Committee: Li, Yen Sung

Date: May 6, 2024

 $\sim 8 \sim$

INDEPENDENT AUDITORS' REPORT

(Parent Company Only Financial Statements)

To the Board of Directors and Shareholders of Charoen Pokphand Enterprise (Taiwan) Co., Ltd.

Opinion

We have audited the accompanying parent company only balance sheets of Charoen Pokphand Enterprise (Taiwan) Co., Ltd. (the "Company") as at December 31, 2023 and 2022, and the related parent company only statements of comprehensive income, of changes in equity and of cash flows for the years then ended, and notes to the parent company only financial statements, including a summary of material accounting policies.

In our opinion, the accompanying parent company only financial statements present fairly, in all material respects, the financial position of the Company as at December 31, 2023 and 2022, and its financial performance and its cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

Basis for opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the parent company only financial statements section of our report. We are independent of the Company in accordance with the Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the Company's 2023 parent company only financial statements. These matters were addressed in the context of our audit of the parent company only financial statements as a whole and, in forming our opinion thereon, we do not provide a separate opinion on these matters.

Key audit matters for the Company's 2023 parent company only financial statements are stated as follows:

Evaluation of net realisable value of inventories

Description

Refer to Note 4(12) for accounting policies adopted for the valuation of inventories, Note 5(2) for uncertainty of accounting estimates and assumptions of valuation of inventories, and Note 6(5) for details of inventories. As at December 31, 2023, the carrying amount of inventories and allowance for inventory valuation losses amounted to NT\$2,181,770 thousand and NT\$7,600 thousand, respectively.

The main activities of the Company are the manufacturing and sales of animal feeds, fresh and processed meat products. As the market prices are affected by changes in macro-economic environment, there is a higher risk of inventory valuation losses. In addition, the evaluation of net realisable value of inventories is subject to management's judgement, and considering that feeds, fresh and processed meat products comprise most of the Company's inventories which is significant to the financial statements, the evaluation of net realisable value of inventories was identified as a key audit matter.

How our audit addressed the matter

We performed the following audit procedures in respect of the above key audit matter:

- 1. Based on our understanding of the Company's operations and related industry, assessed the reasonableness of related policies and procedures applied to the net realisable value of inventories and ascertained the consistent application.
- Obtained statements of net realisable value of inventories as at the balance sheet date, validated source data of merchandise prices and recalculated the provision for inventory valuation losses in order to confirm consistent application of respective procedures and policies.

Measurement of biological assets

Description

Refer to Note 4(14) for accounting policies adopted for biological assets, Note 5(2) for uncertainty of accounting estimates and assumptions in measuring fair value of biological assets, and Note 6(7) for details of biological assets. As at December 31, 2023, the carrying amount of biological assets amounted to NT\$2,364,278 thousand.

The Company's biological assets is mainly comprised of broiler chicken, breeder chicken, fattening swine and breeder swine, etc. Except when the fair value cannot be reliably measured, biological assets are measured at fair value less costs to sell on initial recognition and at the end of each reporting period. As the market prices of fresh, processed meat, livestock and poultry are affected by animal epidemic and market demand in Taiwan, biological assets with active market prices have a higher risk of fluctuations in fair value. Since the amount of biological assets is significant to the financial statements and the methods adopted in measuring each category of biological assets, market prices applied and items accounted for as costs to sell are all subject to management's judgement and with high uncertainty, the measurement of biological assets was identified as a key audit matter.

How our audit addressed the matter

We performed the following audit procedures in respect of the above key audit matter:

- 1. Based on our understanding of the Company's operations and related industry, assessed the reasonableness of related policies and procedures applied in measuring biological assets, and ascertained the consistent application.
- 2. As at the balance sheet date, ascertained that all the active market prices information are available and reliable for biological assets measured at fair value less costs to sell. Also, validated source data of active market prices and the reasonableness of the major components of costs to sell.

Responsibilities of management and those charged with governance for the parent company only financial statements

Management is responsible for the preparation and fair presentation of the parent company only financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations that came into effect as endorsed by the Financial Supervisory Commission, and for such internal control as management determines is necessary to enable the preparation of parent company only financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the parent company only financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including the Audit Committee, are responsible for overseeing the Company's financial reporting process.

Auditors' responsibilities for the audit of the parent company only financial statements

Our objectives are to obtain reasonable assurance about whether the parent company only financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these parent company only financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and professional skepticism throughout the audit. We also:

- 1. Identify and assess the risks of material misstatement of the parent company only financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- 3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the parent company only financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions

- 4. are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- 5. Evaluate the overall presentation, structure and content of the parent company only financial statements, including the disclosures, and whether the parent company only financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- 6. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the parent company only financial statements. We are responsible for the direction, supervision and performance of the audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the parent company only financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Lin, Yi-Fan	Liao, Fu-Ming	
For and on Behalf of Pricewaterhous	seCoopers, Taiwan	
March 11, 2024		

The accompanying parent company only financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying parent company only financial statements and independent auditors' report are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

CHAROEN POKPHAND ENTERPRISE (TAIWAN) CO., LTD. PARENT COMPANY ONLY BALANCE SHEETS DECEMBER 31, 2023 AND 2022 (Expressed in thousands of New Taiwan dollars)

	Assets		December 31, 2023 AMOUNT	 December 31, 2022 AMOUNT %			
-	Current assets	Notes		alviocivi		 7HVIOCIVI	
1100	Cash and cash equivalents	6(1)	\$	139,001	1	\$ 122,778	-
1150	Notes receivable, net	6(4)		351,478	1	375,832	2
1170	Accounts receivable, net	6(4)		2,261,181	9	2,413,462	10
1180	Accounts receivable - related parties	7		131,556	1	127,147	1
1200	Other receivables			15,740	-	50,746	-
1210	Other receivables - related parties	7		343	-	207	-
1220	Current income tax assets			-	-	6,284	-
130X	Inventories, net	6(5)		2,174,170	9	2,472,937	10
1400	Biological assets - current	6(7)		1,823,064	7	1,842,955	8
1410	Prepayments			342,008	1	393,245	2
1470	Other current assets	6(1) and 8		9,650		9,650	
11XX	Total current assets			7,248,191	29	7,815,243	33
	Non-current assets		_				
1510	Non-current financial assets at fair	6(2)					
	value through profit or loss			144,000	1	-	-
1517	Non-current financial assets at fair	6(3)					
	value through other comprehensive						
	income			1,277,060	5	972,692	4
1550	Investments accounted for using	6(6)					
	equity method			2,055,082	8	2,413,926	10
1600	Property, plant and equipment, net	6(8) and 8		12,919,837	52	11,388,585	48
1755	Right-of-use assets	6(9)		337,994	2	340,373	2
1780	Intangible assets	6(10)		35,210	-	3,126	-
1830	Biological assets - non-current	6(7)		541,214	2	502,089	2
1840	Deferred income tax assets	6(25)		77,455	-	50,427	-
1900	Other non-current assets			141,003	1	 118,456	1
15XX	Total non-current assets			17,528,855	71	 15,789,674	67
1XXX	Total assets		\$	24,777,046	100	\$ 23,604,917	100

(Continued)

CHAROEN POKPHAND ENTERPRISE (TAIWAN) CO., LTD. PARENT COMPANY ONLY BALANCE SHEETS DECEMBER 31, 2023 AND 2022 (Expressed in thousands of New Taiwan dollars)

				December 31, 2023		 December 31, 2022	
-	Liabilities and Equity	Notes	A	AMOUNT		 AMOUNT	
	Current liabilities						
2100	Short-term borrowings	6(11)	\$	3,034,040	12	\$ 3,651,097	15
2110	Short-term notes and bills payable	6(12)		978,405	4	938,148	4
2120	Current financial liabilities at fair	6(2)					
	value through profit or loss			-	-	11,791	-
2150	Notes payable			599,749	3	590,631	3
2160	Notes payable - related parties	7		33,701	-	188	-
2170	Accounts payable			764,997	3	874,711	4
2180	Accounts payable - related parties	7		31,599	-	19,314	-
2200	Other payables			1,008,357	4	822,697	3
2220	Other payables - related parties	7		9,966	-	27,109	-
2230	Current income tax liabilities			370,071	2	218,477	1
2280	Current lease liabilities			27,573	-	29,442	-
2320	Long-term liabilities, current portion	6(13)		264,286	1	 648,095	3
21XX	Total current liabilities			7,122,744	29	7,831,700	33
	Non-current liabilities						
2540	Long-term borrowings	6(13) and 8		7,536,667	31	6,391,905	27
2570	Deferred income tax liabilities	6(25)		43,301	-	41,930	-
2580	Non-current lease liabilities			293,501	1	299,974	2
2600	Other non-current liabilities	6(14)		27,509		 42,440	
25XX	Total non-current liabilities			7,900,978	32	6,776,249	29
2XXX	Total liabilities			15,023,722	61	14,607,949	62
	Equity attributable to owners of		_	_			
	parent						
	Share capital	6(15)					
3110	Common stock			2,947,901	12	2,947,901	12
	Capital surplus	6(16)					
3200	Capital surplus			10,534	-	6,640	-
	Retained earnings	6(17)					
3310	Legal reserve			1,340,668	5	1,181,684	5
3350	Unappropriated retained earnings			4,786,803	19	3,713,594	16
	Other equity interest						
3400	Other equity interest			667,418	3	1,147,149	5
3XXX	Total equity			9,753,324	39	8,996,968	38
	Significant contingent liabilities and	9	_				
	unrecognised contract commitments						
	Significant events after the balance	11					
	sheet date						
3X2X	Total liabilities and equity		\$	24,777,046	100	\$ 23,604,917	100

CHAROEN POKPHAND ENTERPRISE (TAIWAN) CO., LTD. PARENT COMPANY ONLY STATEMENTS OF COMPREHENSIVE INCOME YEARS ENDED DECEMBER 31, 2023 AND 2022 (Expressed in thousands of New Taiwan dollars, except earnings per share amount)

				Ye	ar ended l	Decen	nber 31	
				2023			2022	
	Items	Notes		AMOUNT	%		AMOUNT	%
4000	Operating revenue	6(18) and 7	\$	27,235,093	100	\$	26,895,450	100
5000	Operating costs	6(4)(24) and 7	(22,453,967)	(82)	(23,254,925) (87)
5950	Net operating margin			4,781,126	18		3,640,525	13
	Operating expenses	6(24) and 7						
5100	Selling and marketing expenses		(1,114,633)	(4)	(976,648) (4)
5200	General and administrative expenses		(742,252)	(3)	(682,635) (2
5450	Expected credit impairment (loss)	12(2)	·			,	,	
	gain	. /	(23,264)	-		442	-
6000	Total operating expenses		(1,880,149)	(7)	(1,658,841) (6
6500	Other income and expenses, net	6(7)(19)		37,910		_	21,509	
6900	Operating profit	*(,)(->)		2,938,887	11		2,003,193	7
,,,,	Non-operating income and expenses		-	2,,,,,,,,,			2,005,155	
7100	Interest income	6(20)		2,001	_		504	_
7010	Other income	6(21) and 7		26,623			33,578	
7020	Other gains and losses	6(22)		25,784	_	(4,947)	_
7050	Finance costs	6(23)	(-	(131,394)	-
7070	Share of profit of associates and joint	` /	(187,695)	-	(131,394)	-
/0/0		0(0)						
	ventures accounted for using equity			21.690			20.220	
7000	method			21,680			29,338	
7000	Total non-operating income and		,	111 (07)		,	72.021)	
	expenses		(111,607)		(72,921)	
7900	Profit before income tax		,	2,827,280	11		1,930,272	7
7950	Income tax expense	6(25)	(558,315)	(2)	<u></u>	374,892) (1)
8200	Profit for the year		\$	2,268,965	9	\$	1,555,380	6
	Other comprehensive income							
	Components of other comprehensive							
	income that will not be reclassified to							
	profit or loss							
8311	Actuarial (loss) gain on defined	6(14)						
	benefit plan	` /	(\$	4,567)	_	\$	41,468	_
3316	Unrealised gain or loss on financial		(+	-,,		•	,	
	assets at fair value through other							
	comprehensive income		(170,470)	(1)		31,103	_
8330	Share of other comprehensive loss of	6(6)	(170,170)	(-)		51,105	
,550	associates and joint ventures	0(0)						
	accounted for using equity method,							
	components of other comprehensive							
	income that will not be reclassified to							
	profit or loss		(341,049)	(1)	(103,980)	
8349	1	6(25)	(341,049)	(1)	(103,980)	-
5349	Income tax related to components of	0(23)						
	other comprehensive income that							
	will not be reclassified to profit or			25.006		,	14.514)	
	loss			35,006			14,514)	
8310	Other comprehensive loss that will							
	not be reclassified to profit or loss		(481,080)	(2)	(45,923)	
	Components of other comprehensive							
	income that will be reclassified to							
	profit or loss							
8361	Currency translation differences of	6(6)						
	foreign operations		(2,013)	-		160,418	-
8360	Other comprehensive (loss)					-		
	income that will be reclassified to							
	profit or loss		(2,013)	_		160,418	_
300	Total other comprehensive (loss)							
.500	income for the year		(\$	483,093)	(2)	\$	114,495	_
2500	Ţ.		(4	+65,075)		Ψ	117,773	
3500	Total comprehensive income for the		Φ.	1 505 053	_	•	1 660 055	_
	year		\$	1,785,872	7	\$	1,669,875	6
	Earnings per share (in dollars)	6(26)						
9750	Basic earnings per share		\$		7.70	\$		5.28
9850	Diluted earnings per share		\$		7.69	\$		5.27
	~ .							

CHAROEN POKPHAND ENTERPRISE (TAIWAN) CO., LTD. PARENT COMPANY ONLY STATEMENTS OF CHANGES IN EQUITY YEARS ENDED DECEMBER 31, 2023 AND 2022 (Expressed in thousands of New Taiwan dollars)

							Retained	l Ea	rnings		Other Equi	ty In	terest		
	Notes	<u>Co</u>	ommon stock	<u>Ca</u>	pital surplus	. <u>L</u>	egal reserve	U1	nappropriated retained earnings	stat trar differ fo	nancial ements aslation rences of oreign erations	gain from me fa thro	nrealised ns (losses) n financial assets casured at air value ough other prehensive	Tota	l equity_
2022															
Balance at January 1, 2022		\$	2,679,910	\$	4,666	\$	1,044,641	\$	3,332,757 (\$	169,212)	\$	1,236,330	\$	8,129,092
Profit for the year	-		-		-				1,555,380	-	<u> </u>		-,===,===		1,555,380
Other comprehensive income (loss)			-		-		-		34,464		160,418 (80,387)		114,495
Total comprehensive income (loss)	_		-		-		_		1,589,844		160,418 (80,387)		1,669,875
Appropriations of 2021 earnings:	6(17)														
Legal reserve			-		-		137,043(137,043)		-		-		-
Cash dividends			-		=		-(803,973)		-		- (803,973)
Stock dividends			267,991		1.074		-(267,991)		-		-		1.074
Capital surplus - dividends not received by sharehold	ders _	Ф.	2 0 4 7 0 0 1	Φ	1,974	Φ.	1 101 (04	Φ	2 712 504	Ф	0.704	Φ	1 155 042		1,974
Balance at December 31, 2022	=	\$	2,947,901	\$	6,640	\$	1,181,684	\$	3,713,594 (\$	8,794)	\$	1,155,943	\$	8,996,968
2023 Balance at January 1, 2023		\$	2,947,901	\$	6,640	\$	1,181,684	\$	3,713,594 (\$	8,794)	\$	1,155,943	\$	8,996,968
Profit for the year	-	Þ	2,947,901	Ф	0,040	Ф		Ф	2,268,965	Þ	0,/94)	Ф	1,133,943		2,268,965
Other comprehensive loss			- -		- -		-(3,362)(2,013)(477,718)(483,093)
Total comprehensive income (loss)	-		_		_				2,265,603 (2,013)(477,718)		1,785,872
Appropriations of 2022 earnings:	6(17)								,,						
Legal reserve	. ,		-		-		158,984(158,984)		-		-		-
Cash dividends			-		-		-(1,031,765)		-		- (1,031,765)
Capital surplus - dividends not received by sharehole	ders		-		1,758		-		-		-		-		1,758
Change in ownership interests in subsidiaries			-		_		-(1,645)		-		- (1,645)
Change in other capital surplus	_	Φ.	-	Φ	2,136	Φ.	- 1 240 660	Φ.		Φ.	10.005	Φ.	-	Φ.	2,136
Balance at December 31, 2023	=	\$	2,947,901	\$	10,534	\$	1,340,668	\$	4,786,803 (\$	10,807)	\$	678,225	\$	9,753,324

CHAROEN POKPHAND ENTERPRISE (TAIWAN) CO., LTD. PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS YEARS ENDED DECEMBER 31, 2023 AND 2022

(Expressed in thousands of New Taiwan dollars)

	Year ended Dec				ember 31			
	Note	s	2023		2022			
CASH FLOWS FROM OPERATING ACTIVITIES								
Profit before tax		\$	2,827,280	\$	1,930,272			
Adjustments								
Adjustments to reconcile profit (loss)								
Provision for (gain on reversal of) loss on inventory	6(5)		2,600	(1,120)			
Expected credit impairment loss (gain)	12(2)		23,264	(442			
Depreciation	6(8)(24)		888,079		818,696			
Depreciation of right-of-use assets	6(9)(24)		54,416		49,439			
Amortisation	6(24)		22,303		5,846			
Change in fair value less cost to sell of biological	6(7)(19)							
assets	()()	(37,910)	(21,509			
Interest income	6(20)	ì	2,001)	Ì	504			
Dividend income	6(2)(21)	ì	13,621)		24,463			
Interest expense	6(23)		187,695		131,394			
(Gain) loss on financial assets at fair value through	*(==)		,		,			
profit or loss		(5,791)		11,791			
Gain on disposal of property, plant and equipment	6(22)	ì	5,553)	(4,285			
Gain arising from lease modifications	6(22)	ì	856)		201			
Share of profit or loss of associates and joint	6(6)	(050)	(201			
ventures accounted for using equity method	0(0)	(21,680)	(29,338			
Changes in operating assets and liabilities		(21,000)	(27,550			
Changes in operating assets and hadmites Changes in operating assets								
Notes receivable			24,354		19,120			
Notes receivable - related parties			24,334		3,951			
Accounts receivable			129,016	(308,242			
Accounts receivable - related parties		(4,408)	(14,599			
Other receivables		(35,004	(32,971			
Other receivables - related parties		(· · · · · · · · · · · · · · · · · · ·	(
		(136)	(748 040			
Inventories			296,167	(748,940			
Biological assets			18,676	(403,996			
Prepayments			51,593	(574			
Changes in operating liabilities			0.110		150.065			
Notes payable			9,118	,	158,967			
Notes payable - related parties			33,513	(4,067			
Accounts payable		(109,714)		99,215			
Accounts payable - related parties			12,285	(6,935			
Other payables			60,957		118,117			
Other payables - related parties		(17,143)		3,494			
Net defined benefit liability		(19,497	(19,308			
Cash inflow generated from operations			4,438,010		1,728,665			
Cash paid for income tax		(402,483)	(313,753			
D C 1 C:			11,396					
Refund of income tax			11,390					

(Continued)

CHAROEN POKPHAND ENTERPRISE (TAIWAN) CO., LTD. PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS YEARS ENDED DECEMBER 31, 2023 AND 2022

(Expressed in thousands of New Taiwan dollars)

(Expressed in thou	isands of New 1a	iwan uunai	Year ended l	Decemb	per 31
	Notes		2023		2022
CASH FLOWS FROM INVESTING ACTIVITIES					
Acquisition of financial assets at fair value through profit	7				
or loss		(\$	150,000)	\$	-
Acquisition of financial assets at fair value through other					
comprehensive income		(474,837)		-
Acquisition of investment accounted for using the equity					
method			-	(51,000)
Acquisition of property, plant and equipment	6(27)	(2,304,690)	(1,976,977)
Proceeds from disposal of property, plant and equipment			15,105		9,378
Acquisition of intangible assets	6(10)	(49,639)	(1,151)
Increase in other non-current assets		(27,296)	(15,003)
Cash receipt for interest			2,001		504
Cash receipt for dividends			49,438		55,126
Net cash flows used in investing activities		(2,939,918)	(1,979,123
CASH FLOWS FROM FINANCING ACTIVITIES					
(Decrease) increase in short-term borrowings		(617,057)		880,067
Increase (decrease) in short-term notes and bills payable			40,257	(51,171)
Payment of lease liabilities	6(9)	(59,523)	(47,734)
Proceeds from long-term borrowings			10,920,000		8,280,000
Payment of long-term borrowings		(10,159,048)	(7,570,000)
Cash payment for interest		(187,540)	(128,652)
Cash dividends paid to owners of parent	6(17)	(1,031,765)	(803,973)
Capital surplus - dividends not received by shareholders			-		1,974
Capital surplus - dividends not received by shareholders					
and others			3,894		<u> </u>
Net cash flows (used in) from financing activities		(1,090,782)		560,511
Net increase (decrease) in cash and cash equivalents			16,223	(3,700)
Cash and cash equivalents at beginning of year	6(1)		122,778		126,478
Cash and cash equivalents at end of year	6(1)	\$	139,001	\$	122,778

INDEPENDENT AUDITORS' REPORT

(Consolidated Financial Statements)

To the Board of Directors and Shareholders of Charoen Pokphand Enterprise (Taiwan) Co., Ltd.

Opinion

We have audited the accompanying consolidated balance sheets of Charoen Pokphand Enterprise (Taiwan) Co., Ltd. and its subsidiaries (the "Group") as at December 31, 2023 and 2022, and the related consolidated statements of comprehensive income, of changes in equity and of cash flows for the years then ended, and notes to the consolidated financial statements, including a summary of material accounting policies.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Group as at December 31, 2023 and 2022, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations that came into effect as endorsed by the Financial Supervisory Commission.

Basis for opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the consolidated financial statements section of our report. We are independent of the Group in accordance with the Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the Group's 2023 consolidated financial statements. These matters were addressed in the context of our audit of the consolidated financial statements as a whole and, in forming our opinion thereon, we do not provide a separate opinion on these matters.

Key audit matters for the Group's 2023 consolidated financial statements are stated as follows:

Evaluation of net realisable value of inventories

Description

Refer to Note 4(13) for accounting policies adopted for the valuation of inventories, Note 5(2) for uncertainty of accounting estimates and assumptions of valuation of inventories, and Note 6(5) for details of inventories. As at December 31, 2023, the carrying amount of inventories and allowance for inventory valuation losses amounted to NT\$2,400,181 thousand and NT\$21,309 thousand, respectively.

The main activities of the Group are the manufacturing and sales of animal feeds, fresh and processed meat products. As the market prices are affected by changes in macro-economic environment, there is a higher risk of inventory valuation losses. In addition, the evaluation of net realisable value of inventories is subject to management's judgement, and considering that feeds, fresh and processed meat products comprise most of the Group's inventories which is significant to the financial statements, the evaluation of net realisable value of inventories was identified as a key audit matter.

How our audit addressed the matter

We performed the following audit procedures in respect of the above key audit matter:

1. Based on our understanding of the Group's operations and related industry, assessed the reasonableness of related policies and procedures applied to the net realisable value of inventories, and ascertained the consistent application.

2. Obtained statements of net realisable value of inventories as at the balance sheet date, validated source data of merchandise prices and recalculated the provision for inventory valuation losses in order to confirm consistent application of related procedures and policies.

Measurement of biological assets

Description

Refer to Note 4(15) for accounting policies adopted for biological assets, Note 5(2) for uncertainty of accounting estimates and assumptions in measuring fair value of biological assets, and Note 6(6) for details of biological assets. As at December 31, 2023, the carrying amount of biological assets amounted to NT\$2,530,206 thousand.

The Group's biological assets is mainly comprised of broiler chicken, breeder chicken, fattening swine and breeder swine, etc. Except when the fair value cannot be reliably measured, biological assets are measured at fair value less costs to sell on initial recognition and at the end of each reporting period. As the market prices of fresh, processed meat, livestock and poultry are affected by animal epidemic and market demand in Taiwan, biological assets with active market prices have a higher risk of fluctuations in fair value. Since the amount of biological assets is significant to the financial statements and the methods adopted in measuring each category of biological assets, market prices applied and items accounted for as costs to sell are all subject to management's judgement and with high uncertainty, the measurement of biological assets was identified as a key audit matter.

How our audit addressed the matter

We performed the following audit procedures in respect of the above key audit matter:

- 1. Based on our understanding of the Group's operations and related industry, assessed the reasonableness of related policies and procedures applied in measuring biological assets, and ascertained the consistent application.
- As at the balance sheet date, ascertained that all the active market prices information are available and reliable for biological assets measured at fair value less costs to sell. Also, validated the source data of active market prices and the reasonableness of the major components of costs to sell.

Other matter - Parent company only financial reports

We have audited and expressed an unqualified opinion on the parent company only financial statements of Charoen Pokphand Enterprise (Taiwan) Co., Ltd. as at and for the years ended December 31, 2023 and 2022.

Responsibilities of management and those charged with governance for the consolidated financial statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and the International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations, and SIC Interpretations that came into effect as endorsed by the Financial Supervisory Commission, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including the Audit Committee, are responsible for overseeing the Group's financial reporting process.

Auditors' responsibilities for the audit of the consolidated financial statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgement and professional skepticism throughout the audit. We also:

- 1. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.
- 2. Obtain an understanding of internal controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal controls.
- 3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- 4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- 5. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- 6. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal controls that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Lin, Yi-Fan	Liao, Fu-Ming
For and on Behalf of PricewaterhouseCoopers, Taiwar	1
March 11, 2024	

The accompanying consolidated financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying consolidated financial statements and independent auditors' report are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

CHAROEN POKPHAND ENTERPRISE (TAIWAN) CO., LTD. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS DECEMBER 31, 2023 AND 2022 (Expressed in thousands of New Taiwan dollars)

	ASSETS		 December 31, 2023 AMOUNT	%	 December 31, 2022 AMOUNT	%
	Current assets	Notes				
1100	Cash and cash equivalents	6(1)	\$ 275,585	1	\$ 311,085	1
1150	Notes receivable, net	6(4)	358,295	1	411,234	2
1160	Notes receivable due from related	7				
	parties, net		1,558	-	2,756	-
1170	Accounts receivable, net	6(4)	2,577,965	10	2,730,874	10
1180	Accounts receivable - related parties	7	74,101	-	66,171	-
1200	Other receivables		18,848	-	54,377	-
1210	Other receivables - related parties	7	43	-	228	-
1220	Current income tax assets		-	-	6,284	-
130X	Inventories, net	6(5)	2,378,872	9	2,648,075	10
1400	Biological assets - current	6(6)	1,988,992	7	2,057,573	8
1410	Prepayments		364,262	1	412,472	2
1470	Other current assets	6(1) and 8	 9,650		 9,650	
11XX	Total current assets		 8,048,171	29	 8,710,779	33
1	Non-current assets					
1517	Non-current financial assets at fair	6(3)				
	value through other comprehensive					
	income		2,620,673	10	2,659,785	10
1550	Investments accounted for using	6(7)				
	equity method		91,399	-	94,713	-
1600	Property, plant and equipment, net	6(8) and 8	15,332,016	56	13,789,365	52
1755	Right-of-use assets	6(9)	355,367	1	366,762	1
1780	Intangible assets	6(10)	35,216	-	3,155	-
1830	Biological assets - non-current	6(6)	541,214	2	502,089	2
1840	Deferred income tax assets	6(27)	185,953	1	130,607	1
1900	Other non-current assets		 159,788	1	 136,490	1
15XX	Total non-current assets		19,321,626	71	17,682,966	67
1XXX	Total assets		\$ 27,369,797	100	\$ 26,393,745	100

(Continued)

CHAROEN POKPHAND ENTERPRISE (TAIWAN) CO., LTD. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS DECEMBER 31, 2023 AND 2022 (Expressed in thousands of New Taiwan dollars) December 31, 2023

		1	December 31, 20			December 31, 2022		
	LIABILITIES AND EQUITY	Notes		AMOUNT	<u>%</u>	AMOUNT	%	
	Current liabilities							
2100	Short-term borrowings	6(11)	\$	3,561,041	13	\$ 4,265,097	16	
2110	Short-term notes and bills payable	6(12)		1,028,150	4	987,963	4	
2120	Current financial liabilities at fair	6(2)						
	value through profit or loss			-	-	11,791	-	
2150	Notes payable			738,747	3	681,467	3	
2160	Notes payable - related parties	7		25,465	-	13,389	-	
2170	Accounts payable			846,988	3	1,002,088	4	
2180	Accounts payable - related parties	7		23,300	-	19,185	-	
2200	Other payables	6(13)		1,084,003	4	895,378	3	
2220	Other payables - related parties	7		12,254	-	30,574	-	
2230	Current income tax liabilities			387,605	2	228,618	1	
2280	Current lease liabilities			30,721	-	35,888	-	
2320	Long-term liabilities, current portion	6(14) and 8		365,488	1	703,597	3	
21XX	Total current liabilities			8,103,762	30	8,875,035	34	
	Non-current liabilities							
2540	Long-term borrowings	6(14) and 8		8,676,756	32	7,639,663	29	
2570	Deferred income tax liabilities	6(27)		44,639	-	43,046	-	
2580	Non-current lease liabilities			298,413	1	308,529	1	
2600	Other non-current liabilities	6(15)		23,810		39,708		
25XX	Total non-current liabilities			9,043,618	33	8,030,946	30	
2XXX	Total liabilities			17,147,380	63	16,905,981	64	
	Equity attributable to owners of							
	parent							
	Share capital	6(16)						
3110	Common stock			2,947,901	11	2,947,901	11	
	Capital surplus	6(17)						
3200	Capital surplus			10,534	-	6,640	-	
	Retained earnings	6(18)						
3310	Legal reserve			1,340,668	5	1,181,684	5	
3350	Unappropriated retained earnings			4,786,803	17	3,713,594	14	
	Other equity interest							
3400	Other equity interest			667,418	2	1,147,149	4	
31XX	Equity attributable to owners of							
	the parent			9,753,324	35	8,996,968	34	
36XX	Non-controlling interest			469,093	2	490,796	2	
3XXX	Total equity			10,222,417	37	9,487,764	36	
	Significant contingent liabilities and	9						
	unrecognised contract commitments							
	Significant events after the balance	11						
	sheet date							
3X2X	Total liabilities and equity		\$	27,369,797	100	\$ 26,393,745	100	

CHAROEN POKPHAND ENTERPRISE (TAIWAN) CO., LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME YEARS ENDED DECEMBER 31, 2023 AND 2022 (Expressed in thousands of New Taiwan dollars, except for earnings per share amounts)

			Year ended December 31						
				2023			2022		
	Items	Notes		AMOUNT	<u>%</u>		AMOUNT	%	
4000	Operating revenue	6(19) and 7	\$	29,159,749	100	\$	28,959,220	100	
5000	Operating costs	6(5)(25)(26) and							
		7	(24,157,745) (83)	(25,082,443) (87)	
5950	Net operating margin			5,002,004	17		3,876,777	13	
	Operating expenses	6(25)(26) and 7							
6100	Selling and marketing expenses		(1,279,208) (4)	(1,151,245) (4)	
6200	General and administrative								
	expenses		(809,638) (3)	(750,752) (2)	
6450	Expected credit impairment	12(2)							
	(loss) gain		(23,734)			7,390		
6000	Total operating expenses		(2,112,580) (7)	(1,894,607) (6)	
6500	Other income and expenses, net	6(6)(20)		37,910			21,509		
6900	Operating profit			2,927,334	10		2,003,679	7	
	Non-operating income and								
	expenses								
7100	Interest income	6(21)		2,741	-		711	-	
7010	Other income	6(22) and 7		49,494	-		74,880	-	
7020	Other gains and losses	6(23) and 7		47,252	-		1,853	-	
7050	Finance costs	6(24)	(208,594)	-	(147,433) (1)	
7060	Share of loss of associates and	6(7)							
	joint ventures accounted for								
	using equity method		(3,314)		(5,447)		
7000	Total non-operating income								
	and expenses		(112,421)		(75,436) (1)	
7900	Profit before income tax			2,814,913	10		1,928,243	6	
7950	Income tax expense	6(27)	(558,477) (_	2)	(378,069) (1)	
8200	Profit for the year		\$	2,256,436	8	\$	1,550,174	5	

(Continued)

CHAROEN POKPHAND ENTERPRISE (TAIWAN) CO., LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME YEARS ENDED DECEMBER 31, 2023 AND 2022

(Expressed in thousands of New Taiwan dollars, except for earnings per share amounts)

			Year ended December 31							
				2023			2022			
	Items	Notes		AMOUNT	% 0		AMOUNT			
	Other comprehensive income									
	Components of other									
	comprehensive income that will									
	not be reclassified to profit or									
	loss	- ()								
8311	Actuarial (loss) gain on defined	6(15)	(A	2.015		ф	42.054			
0216	benefit plans		(\$	3,917)	-	\$	43,974	-		
8316	Unrealised gain or loss on									
	financial assets at fair value									
	through other comprehensive			£11 011) /	2)	,	74.1(7)			
0240	income	((27)	(511,811) (2)	(74,167)	-		
8349	Income tax related to	6(27)								
8310	components of other									
	comprehensive income that will not be reclassified to profit or									
	loss			34,876		,	15 (015)			
9210				34,870		<u></u>	15,015)			
8310	Other comprehensive loss that									
	will not be reclassified to profit or loss		(480,852) (2)	(45,208)			
				460,632) (2)	_	43,208)			
	Components of other comprehensive income that will									
	be reclassified to profit or loss									
8361	Currency translation differences									
0301	of foreign operations		(2,013)	_		160,418	1		
8360	Other comprehensive (loss)			2,013)	<u>_</u>		100,410			
8300	income that will be reclassified									
	to profit or loss		(2,013)	_		160,418	1		
8300	Total other comprehensive (loss)			2,013)			100,110			
0500	income for the year		(\$	482,865) (2)	\$	115,210	1		
8500	Total comprehensive income for		(Ψ	102,003)		Ψ	113,210			
0300	the year		\$	1,773,571	6	\$	1,665,384	6		
	Profit (loss) attributable to:		Ψ	1,773,371		Ψ	1,005,504			
8610	Owners of the parent		\$	2,268,965	8	\$	1,555,380	5		
8620	Non-controlling interest		(12,529)	-	φ (5,206)	_		
0020	Non-controlling interest		\$	2,256,436	8	\$	1,550,174	5		
	Comprehensive income (loss)		Ψ	2,230,430		Ψ	1,550,174			
	attributable to:									
8710	Owners of the parent		\$	1,785,872	6	\$	1,669,875	6		
8720	Non-controlling interest		, (12,301)	-	φ (4,491)	C		
8720	Non-controlling interest		\$		6	\$	1,665,384	6		
			Φ	1,773,571	0	Φ	1,003,364			
	Earnings per share (in dollars)	6(28)								
9750	Basic earnings per share	0(20)	•		7.70	\$		5.28		
			\$							
9850	Diluted earnings per share		\$		7.69	\$_		5.27		

The accompanying notes are an integral part of these consolidated financial statements.

CHAROEN POKPHAND ENTERPRISE (TAIWAN) CO., LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY YEARS ENDED DECEMBER 31, 2023 AND 2022

(Expressed in thousands of New Taiwan dollars)

Equity attributable to owners of the parent Retained Earnings Other Equity Interest Unrealised gains (losses) from Financial financial assets statements measured at fair value through translation differences of other comprehensive Non-controlling Share capital -Unappropriated foreign Notes common stock Capital surplus Legal reserve retained earnings operations income Total interest Total equity 2022 Balance at January 1, 2022 \$ 2,679,910 4,666 \$ 1,044,641 3,332,757 (\$ 169,212) 1,236,330 8,129,092 463,915 8,593,007 1,555,380 1,555,380 5,206) 1,550,174 Profit (loss) for the year Other comprehensive income (loss) 34,464 160,418 80,387) 114,495 715 115,210 Total comprehensive income (loss) 1,589,844 160,418 80,387 1,669,875 4,491 1,665,384 Appropriations of 2021 earnings 6(18) 137,043 137,043) Legal reserve Cash dividends 803,973) 803,973) 803,973) Stock dividends 267,991 267,991) Capital surplus - dividends not received by shareholders 1,974 1,974 1,974 Cash receipt from non-controlling interest of a subsidiary through capital increase in cash 49,000 49,000 Change in non-controlling interests 17,628 17,628) Balance at December 31, 2022 2,947,901 3,713,594 1,155,943 6,640 1,181,684 8,794 8,996,968 490,796 9,487,764 2023 8,996,968 490,796 Balance at January 1, 2023 3,713,594 1,155,943 9,487,764 2,947,901 6,640 1,181,684 8,794) Profit (loss) for the year 2,268,965 2,268,965 12,529) 2,256,436 Other comprehensive income (loss) 2.013) 477,718) 483,093 228 482,865) 3,362 Total comprehensive income (loss) 2,265,603 2,013) 477,718 1,785,872 12,301 1,773,571 Appropriations of 2022 earnings 6(18) Legal reserve 158,984 158,984) Cash dividends to shareholders 1,031,765 1,031,765) 1,031,765) Capital surplus - dividends not received by shareholders 1,758 1,758 1,758 Cash dividends to non-controlling interest 21,047) (21,047) Change in other capital surplus 2,136 2,136 2,136 6(29) Change in ownership interests in subsidiaries 1,645) 1,645) 1,645 Change in non-controlling interests 10,000 10,000

The accompanying notes are an integral part of these consolidated financial statements.

1,340,668

4,786,803

10,807)

678,225

9,753,324

469,093

\$ 10,222,417

10,534

2,947,901

Balance at December 31, 2023

<u>CHAROEN POKPHAND ENTERPRISE (TAIWAN) CO., LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS YEARS ENDED DECEMBER 31, 2023 AND 2022</u>

(Expressed in thousands of New Taiwan dollars)

Notes	•			Year end	ed Decen	nber 31
Profit before tax		Notes		2023		2022
Profit before tax						
Profit before tax						
Adjustments Adjustments to reconcile profit (loss) (Gain) loss on financial asset at fair value through profit or loss Expected credit impairment loss (gain) 12(2) 23,734 (7,390) Depreciation 6(8)(25) 978,119 895,140 Depreciation of right-of-use assets 6(9)(25) 63,431 58,994 Amortisation 6(25) 22,326 5,870 Interest income 6(21) (2,741) (711) Interest expense 6(24) 208,594 147,433 Dividend income 6(3)(22) (37,118) (66,108) Provision for (gain on reversal of) loss on 6(5) inventory Change in fair value less cost to sell of 6(6)(20) biological assets Changes in operating assets and liabilities Changes in operating assets and liabilities Changes in operating assets Notes receivable related parties Accounts receivable - related parties Other receivables - related parties Inventories Biological assets Inventories Shotes payable - related parties Changes in operating liabilities Changes in operating liabilities Changes in operating liabilities Changes in operating assets Notes receivable - related parties Changes in operating assets Notes receivable - related parties Shotes receivable - related parties Changes in operating liabilities Changes in operating assets Notes receivable - related parties Changes in operating liabilities Changes in o	CASH FLOWS FROM OPERATING ACTIVITIES					
Adjustments to reconcile profit (loss) (Gain) loss on financial asset at fair value through profit or loss Expected credit impairment loss (gain) 12(2) 23,734 (7,390) Depreciation of right-of-use assets 6(9)(25) 578,119 895,140 Depreciation of right-of-use assets 6(9)(25) 63,431 58,994 Amortisation 6(25) 22,326 5,870 Interest income 6(21) (2,741) (711) Interest expense 6(24) 208,594 147,433 Dividend income 6(3)(22) (37,118) (66,108) Provision for (gain on reversal of) loss on 6(5) inventory 11,356 (1,681) Change in fair value less cost to sell of 6(6)(20) biological assets (3,7910) (21,509) Share of profit or loss recognised under equity method (3) (3,314 5,447) Gain on disposal of property, plant and 6(23) (37,910) (21,509) Changes in operating assets and liabilities Changes in operating assets and liabilities Changes in operating assets and liabilities Changes in receivable (1,198 1,195) Accounts receivable 1,198 1,195 Accounts receivable - related parties (7,930) (10,464) Other receivables (7,930) (10,464) Other receivable - related parties (1,932) (1,936) Biological assets (7,936) (1,946) Other spayable - related parties (1,932) (1,936) Other spayable - related parties (1,932) (1,936) Other spayable - related parties (1,932) (1,932) Other payables - related parties (1,932) (1,932)	Profit before tax		\$	2,814,913	\$	1,928,243
Gain) loss on financial asset at fair value through profit or loss (11,791) 11,791 Expected credit impairment loss (gain) 12(2) 23,734 (7,390) Depreciation 6(8)(25) 978,119 895,140 Depreciation of right-of-use assets 6(9)(25) 63,431 58,994 Amortisation 6(25) 22,326 5,870 Interest income 6(21) (2,741) (711) Interest expense 6(24) 208,594 147,433 Dividend income 6(3)(22) (37,118) (66,108) Provision for (gain on reversal of) loss on 6(5) inventory 11,356 (1,681)	Adjustments					
through profit or loss Expected credit impairment loss (gain) 12(2) 23,734 (7,390) Depreciation 6(8)(25) 978,119 895,140 Depreciation of right-of-use assets 6(9)(25) 63,431 58,994 Amortisation 6(25) 22,326 5,870 Interest income 6(21) (2,741) (711) Interest expense 6(24) 208,594 147,433 Dividend income 6(3)(22) (37,118) (66,108) Provision for (gain on reversal of) loss on 6(5) inventory 11,356 (1,681) Change in fair value less cost to sell of 6(6)(20) biological assets Share of profit or loss recognised under equity of 670 method Gain on disposal of property, plant and equipment (11,641) (4,392) Gain arising from lease modifications 6(23) (856) (201) Changes in operating assets and liabilities Changes in operating assets and liabilities Changes in operating assets and liabilities Changes in operating assets who is receivable 129,175 (352,643) Accounts receivable - related parties (7,930) (10,464) Other receivables (7,930) (10,464) Other receivables (7,930) (10,464) Other receivables - related parties (7,930) (10,464) Other receivables - 185 (228) Inventories (7,930) (10,464) Prepayments (7,936) (10,464) Prepayments (185 (228) Notes payable - related parties (1,936) (1,948) Other spayable - related parties (1,936) (1,948) Prepayments (1,948) (1,948) (1,948) (1,948) Prepayments (1,948) (1,948) (1,948) (1,948) (1,948) (1,948) (1,948) (1,948) (Adjustments to reconcile profit (loss)					
Expected credit impairment loss (gain) 12(2) 23,734 (7,390) Depreciation 6(8)(25) 978,119 895,140 Depreciation of right-of-use assets 6(9)(25) 63,431 58,994 Amortisation 6(25) 22,326 5,870 Interest income 6(21) (2,741) (711) Interest expense 6(24) 208,594 147,433 Dividend income 6(3)(22) (37,118) (66,108) Provision for (gain on reversal of) loss on 6(5) inventory 11,356 (1,681) Change in fair value less cost to sell of 6(6)(20) Share of profit or loss recognised under equity 6(7) method Gain on disposal of property, plant and 6(23) equipment (11,641) (4,392) equipment (11,641) (4,392) Changes in operating assets and liabilities Changes in operating assets and liabilities Changes in operating assets Notes receivable 11,198 1,195 Accounts receivable 129,175 (352,643) Accounts receivable - related parties (7,930) (10,464) Other receivables - related parties (7,930) (10,464) Other receivables - related parties (7,930) (10,464) Other receivables - related parties (12,076 (27,847) Prepayments (15,000) 151,588 Accounts payable - related parties (15,100) 151,588 Accounts payable - related parties (15,	(Gain) loss on financial asset at fair value					
Depreciation			(11,791)		
Depreciation of right-of-use assets 6(9)(25) 22,326 5,870 Amortisation 6(25) 22,326 5,870 Interest income 6(21) (2,741) (711) Interest expense 6(24) 208,594 147,433 Dividend income 6(3)(22) (37,118) (66,108) Provision for (gain on reversal of) loss on 6(5) inventory 11,356 (1,681) Change in fair value less cost to sell of 6(6)(20) biological assets (37,910) (21,509) Share of profit or loss recognised under equity 6(7) method 3,314 5,447 Gain on disposal of property, plant and 6(23) equipment (11,641) (4,392) Gain arising from lease modifications 6(23) (856) (201) Changes in operating assets and liabilities Changes in operating assets 1,198 1,195 Accounts receivable - related parties 1,198 1,195 Accounts receivable - related parties 1,29,175 (352,643) Accounts receivable - related parties 1,29,175 (352,643) Other receivables - related parties 1,85 (228) Inventories 257,847 (769,168) Biological assets 67,366 (478,474) Prepayments 48,499 (5,043) Changes in operating liabilities 57,280 176,692 Notes payable - related parties 1,51,00 151,588 Accounts payable - related parties 4,115 (2,708) Other payables - related parties 4,115 (1,734) Other payables - related parties 4,115 (1,734) Other payables - related parties 4,115 (1,736) Other payables - rel	Expected credit impairment loss (gain)	12(2)		23,734	(7,390)
Amortisation 6(25) 22,326 5,870 Interest income 6(21) (2,741) (711) Interest expense 6(24) 208,594 147,433 Dividend income 6(3)(22) (37,118) (66,108) Provision for (gain on reversal of) loss on 6(5) inventory 11,356 (1,681) Change in fair value less cost to sell of 6(6)(20) biological assets Share of profit or loss recognised under equity 6(7) method 3,314 5,447 Gain on disposal of property, plant and 6(23) equipment (11,641) (4,392) Gain arising from lease modifications 6(23) (856) (201) Changes in operating assets and liabilities Changes in operating assets Notes receivable						
Interest income		6(9)(25)				58,994
Interest expense		6(25)		22,326		5,870
Dividend income 6(3)(22) (37,118) (66,108)	Interest income	6(21)	((711)
Provision for (gain on reversal of) loss on inventory inventory 11,356 1,681				208,594		147,433
inventory Change in fair value less cost to sell of 6(6)(20) biological assets Share of profit or loss recognised under equity 6(7) method Gain on disposal of property, plant and equity 6(23) equipment Gain arising from lease modifications Changes in operating assets and liabilities Changes in operating assets Notes receivable Notes receivable - related parties Accounts receivable - related parties Other receivables - related parties Biological assets Notes payable - related parties Changes in operating liabilities Changes in operating assets Notes receivable - 129,175 Accounts receivable - 129,175 Accounts receivable - 129,175 Accounts receivable - 129,175 Other receivables - 185 Biological assets Biological assets Accounts receivable - 185 Changes in operating liabilities Changes in operating liabilities Changes in operating liabilities Notes payable - related parties Accounts receivable - 129,175 Accounts receivables - 129,175 Accounts receivables - 129,175 Accounts receivables - 129,175 Accounts receivables - 129,176 Accounts payable - 120,176 Accoun			(37,118)	(66,108)
Change in fair value less cost to sell of biological assets (37,910) (21,509) Share of profit or loss recognised under equity method 3,314 5,447 Gain on disposal of property, plant and equipment (11,641) (4,392) 4,392) Gain arising from lease modifications 6(23) 856) (201) Changes in operating assets and liabilities Changes in operating assets Notes receivable 52,939 4,798 Notes receivable - related parties 1,198 1,195 Accounts receivable - related parties 1,29,175 (352,643) Accounts receivable - related parties 7,930) (10,464) Other receivables - related parties 185 (228) Inventories 257,847 (769,168) Biological assets 67,366 (478,474) Prepayments 48,499 (5,043) Changes in operating liabilities 57,280 (176,692) Notes payable - related parties 12,076 (2,716) Accounts payable - related parties (155,100) (151,588) Accounts payable - related parties (155,100) (151,588) Accounts payable - related parties (18,320) (3,803) Other payables - related parties	Provision for (gain on reversal of) loss on	6(5)				
biological assets Share of profit or loss recognised under equity 6(7) method Gain on disposal of property, plant and equipment Gain arising from lease modifications Changes in operating assets and liabilities Changes in operating assets Notes receivable Notes receivable related parties Accounts receivable - related parties Inventories Inventories Biological assets Notes receivable - related parties Inventories Inventories Souther receivable - related parties Inventories Souther receivable - related parties Inventories Inventories Souther receivable - related parties Inventories Inventor				11,356	(1,681)
Share of profit or loss recognised under equity method 3,314 5,447 Gain on disposal of property, plant and equipment (11,641) (43,92) 43,92) Gain arising from lease modifications 6(23) (856) (201) 201) Changes in operating assets 856) (201) 201) Changes in operating assets 52,939 (4,798) 4,798 Notes receivable related parties 1,198 (1,195) 1,195 Accounts receivable - related parties (29,30) (10,464) 1,195 Accounts receivable - related parties (29,30) (10,464) 1,196 Other receivables - related parties 35,529 (35,712) 352,643) Inventories 257,847 (769,168) 228 (10,464) Biological assets 67,366 (478,474) 769,168) Biological assets 67,366 (478,474) 769,168) Notes payable 57,280 (176,692) 5,043) Changes in operating liabilities 12,076 (2,716) 2,716 Accounts payable - related parties 12,076 (2,716) 2,716 Accounts payable - related parties 63,919 (116,571) 31,558 Accounts payable - related parties		6(6)(20)				
method 3,314 5,447 Gain on disposal of property, plant and equipment (11,641) (4,392) Gain arising from lease modifications 6(23) (856) (201) Changes in operating assets and liabilities 856) (201) Changes in operating assets 856) (201) Notes receivable 52,939 (3,798) Notes receivable - related parties 1,198 (1,195) Accounts receivable - related parties (7,930) (10,464) Other receivables - related parties (7,930) (10,464) Other receivables - related parties (7,930) (10,464) Inventories 257,847 (769,168) Biological assets 67,366 (478,474) Prepayments 48,499 (5,043) Changes in operating liabilities 57,280 (76,692) Notes payable - related parties 12,076 (2,716) Accounts payable - related parties (155,100) (151,588) Accounts payable - related parties (155,100) (151,588) Accounts payable - related parties (18,320) (3,803) Other payables - related parties (18,320) (3,803) Other payables - related parties (18,320) (3,803)			(37,910)	(21,509)
Gain on disposal of property, plant and equipment 6(23) (11,641) (4,392) Gain arising from lease modifications 6(23) (856) (201) Changes in operating assets and liabilities Changes in operating assets Notes receivable operating assets 52,939 4,798 Notes receivable - related parties 1,198 1,195 Accounts receivable - related parties (7,930) (10,464) 10,464) Other receivables - related parties 185 (228) 35,529 (35,712) Other receivables - related parties 185 (228) 185 (228) Inventories 257,847 (769,168) 86) 67,366 (478,474) Prepayments 48,499 (5,043) 5,043) Changes in operating liabilities 57,280 176,692 176,692 Notes payable - related parties 12,076 2,716 2,716 Accounts payable - related parties (155,100) 151,588 15,588 Accounts payables - related parties (18,320) 3,803 3,803 Net defined benefit liability (19,815) (19,875) 19,575) Cash inflow generated from operations 4,552,693 (17,34,274) <td< td=""><td>Share of profit or loss recognised under equity</td><td>6(7)</td><td></td><td></td><td></td><td></td></td<>	Share of profit or loss recognised under equity	6(7)				
equipment (11,641) (4,392) Gain arising from lease modifications 6(23) (856) (201) Changes in operating assets Notes receivable 52,939 4,798 Notes receivable - related parties 1,198 1,195 Accounts receivable - related parties 129,175 (352,643) Accounts receivable - related parties (7,930) (10,464) Other receivables - related parties 35,529 (35,712) Other receivables - related parties 185 (228) Inventories 257,847 (769,168) Biological assets 67,366 (478,474) Prepayments 48,499 (5,043) Changes in operating liabilities 57,280 (176,692) Notes payable 57,280 (176,692) Notes payable - related parties 12,076 (2,716) Accounts payables - related parties 63,919 (116,571) Other payables - related parties 63,919 (116,571) Other payables - related parties				3,314		5,447
Gain arising from lease modifications 6(23) (856) 201) Changes in operating assets and liabilities Changes in operating assets Notes receivable 52,939 4,798 Notes receivable - related parties 1,198 1,195 Accounts receivable - related parties (7,930) (10,464) 10,464) Other receivables - related parties (7,930) (10,464) 35,712) Other receivables - related parties 185 (228) 228) Inventories 257,847 (769,168) 769,168) Biological assets 67,366 (478,474) 769,168) Biological assets 67,366 (478,474) 769,168) Notes payments 48,499 (5,043) 5,043) Changes in operating liabilities 12,076 (2,716) 2,716) Notes payable - related parties 12,076 (2,716) 2,716) Accounts payable - related parties (155,100) 151,588) Accounts payables - related parties (18,320) 3,803) Other payables - related parties (18,320) 3,803) Net defined benefit liability		6(23)				
Changes in operating assets and liabilities Changes in operating assets 52,939 4,798 Notes receivable - related parties 1,198 1,195 Accounts receivable - related parties 129,175 (352,643) Accounts receivable - related parties (7,930) (10,464) Other receivables - related parties 185 (228) Inventories 257,847 769,168) Biological assets 67,366 478,474) Prepayments 48,499 5,043) Changes in operating liabilities 57,280 176,692 Notes payable - related parties 12,076 2,716 Accounts payable - related parties (155,100) 151,588 Accounts payables - related parties 4,115 2,708) Other payables - related parties 63,919 116,571 Other payables - related parties (18,320) 3,803 Net defined benefit liability (19,815) (19,575) Cash paid for income tax (423,479) (331,756) Refund of income tax 11,396 -			(,	4,392)
Notes receivable		6(23)	(856)	(201)
Notes receivable 52,939 4,798 Notes receivable - related parties 1,198 1,195 Accounts receivable 129,175 352,643 Accounts receivable - related parties (7,930) 10,464 Other receivables - related parties 35,529 35,712 Other receivables - related parties 185 228 Inventories 257,847 769,168 Biological assets 67,366 478,474 Prepayments 48,499 5,043 Changes in operating liabilities 7,280 176,692 Notes payable - related parties 12,076 2,716 Accounts payable - related parties 4,115 2,708 Other payables - related parties 63,919 116,571 Other payables - related parties 63,919 116,575 Other payables - related parties (18,320) 3,803 Net defined benefit liability (19,815) (19,575) Cash inflow generated from operations 4,552,693 1,734,274 Cash paid for income tax (423,479) 331,756) <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
Notes receivable - related parties						
Accounts receivable Accounts receivable - related parties Other receivables Other receivables Other receivables - related parties Other receivables - related parties Inventories Inventor						,
Accounts receivable - related parties (7,930) (10,464) Other receivables 35,529 (35,712) Other receivables - related parties 185 (228) Inventories 257,847 (769,168) Biological assets 67,366 (478,474) Prepayments 48,499 (5,043) Changes in operating liabilities 57,280 176,692 Notes payable - related parties 12,076 (2,716 Accounts payable - related parties 4,115 (2,708) Other payables - related parties 63,919 (116,571 Other payables - related parties (18,320) 3,803 Net defined benefit liability (19,815) (19,575) Cash inflow generated from operations 4,552,693 (1,734,274 Cash paid for income tax (423,479) (331,756) Refund of income tax 11,396 (-	A			,		,
Other receivables 35,529 (35,712) Other receivables - related parties 185 (228) Inventories 257,847 (769,168) Biological assets 67,366 (478,474) Prepayments 48,499 (5,043) Changes in operating liabilities Tokes payable 176,692 Notes payable - related parties 12,076 (2,716 (Accounts payable - related parties 4,115 (2,708) Other payables - related parties 63,919 (116,571 (Other payables - related parties (18,320) 3,803 (Net defined benefit liability (19,815) (19,575) Cash inflow generated from operations 4,552,693 (1,734,274 (331,756) Refund of income tax (423,479) (331,756)					(
Other receivables - related parties 185 (228) Inventories 257,847 (769,168) Biological assets 67,366 (478,474) Prepayments 48,499 (5,043) Changes in operating liabilities 57,280 176,692 Notes payable - related parties 12,076 2,716 Accounts payable - related parties 4,115 (2,708) Other payables - related parties 63,919 116,571 Other payables - related parties (18,320) 3,803 Net defined benefit liability (19,815) (19,575) Cash inflow generated from operations 4,552,693 1,734,274 Cash paid for income tax (423,479) (331,756) Refund of income tax 11,396 -			((
Inventories 257,847 (769,168) Biological assets 67,366 (478,474) Prepayments 48,499 (5,043)				,	(
Biological assets 67,366 (478,474) Prepayments 48,499 (5,043) Changes in operating liabilities 57,280 176,692 Notes payable - related parties 12,076 2,716 Accounts payable - related parties 155,100) 151,588 Accounts payable - related parties 4,115 (2,708) Other payables 63,919 116,571 Other payables - related parties (18,320) 3,803 Net defined benefit liability (19,815) (19,575) Cash inflow generated from operations 4,552,693 1,734,274 Cash paid for income tax (423,479) (331,756) Refund of income tax 11,396 -	1				(
Prepayments 48,499 (5,043) Changes in operating liabilities 57,280 176,692 Notes payable 57,280 2,716 Accounts payable - related parties 12,076 2,716 Accounts payable - related parties 4,115 (2,708) Other payables 63,919 116,571 Other payables - related parties (18,320) 3,803 Net defined benefit liability (19,815) (19,575) Cash inflow generated from operations 4,552,693 1,734,274 Cash paid for income tax (423,479) (331,756) Refund of income tax 11,396 -					(. ,
Changes in operating liabilities 57,280 176,692 Notes payable 57,280 176,692 Notes payable - related parties 12,076 2,716 Accounts payable (155,100) 151,588 Accounts payable - related parties 4,115 (2,708) Other payables 63,919 116,571 Other payables - related parties (18,320) 3,803 Net defined benefit liability (19,815) (19,575) Cash inflow generated from operations 4,552,693 1,734,274 Cash paid for income tax (423,479) 331,756) Refund of income tax 11,396 -				,	(. ,
Notes payable 57,280 176,692 Notes payable - related parties 12,076 2,716 Accounts payable (155,100) 151,588 Accounts payable - related parties 4,115 (2,708) Other payables 63,919 116,571 Other payables - related parties (18,320) 3,803 Net defined benefit liability (19,815) (19,575) Cash inflow generated from operations 4,552,693 1,734,274 Cash paid for income tax (423,479) 331,756) Refund of income tax 11,396 -				48,499	(5,043)
Notes payable - related parties 12,076 2,716 Accounts payable (155,100) 151,588 Accounts payable - related parties 4,115 (2,708) Other payables 63,919 (116,571) Other payables - related parties (18,320) 3,803) Net defined benefit liability (19,815) (19,575) Cash inflow generated from operations 4,552,693 (1,734,274) 1,734,274) Cash paid for income tax (423,479) (331,756) Refund of income tax 11,396 - -						
Accounts payable (155,100) 151,588 Accounts payable - related parties 4,115 (2,708) Other payables 63,919 (16,571) Other payables - related parties (18,320) 3,803) Net defined benefit liability (19,815) (19,575) Cash inflow generated from operations 4,552,693 (1,734,274) 1,734,274) Cash paid for income tax (423,479) (331,756) Refund of income tax 11,396 - -						,
Accounts payable - related parties 4,115 (2,708) Other payables 63,919 116,571 Other payables - related parties (18,320) 3,803 Net defined benefit liability (19,815) (19,575) Cash inflow generated from operations 4,552,693 1,734,274 Cash paid for income tax (423,479) (331,756) Refund of income tax 11,396 -						
Other payables 63,919 116,571 Other payables - related parties (18,320) 3,803 Net defined benefit liability (19,815) (19,575) Cash inflow generated from operations 4,552,693 1,734,274 Cash paid for income tax (423,479) 331,756) Refund of income tax 11,396 -			(
Other payables - related parties (18,320) 3,803 Net defined benefit liability (19,815) (19,575) Cash inflow generated from operations 4,552,693 1,734,274 Cash paid for income tax (423,479) (331,756) Refund of income tax 11,396 -	* *				(
Net defined benefit liability (19,815) (19,575) Cash inflow generated from operations 4,552,693 1,734,274 Cash paid for income tax (423,479) (331,756) Refund of income tax 11,396 -						
Cash inflow generated from operations 4,552,693 1,734,274 Cash paid for income tax (423,479) (331,756) Refund of income tax 11,396 -			(
Cash paid for income tax (423,479) (331,756) Refund of income tax 11,396 -			((
Refund of income tax 11,396 -				/ /)·-) ·
	*		((331,756)
Net cash flows from operating activities 4,140,610 1,402,518						<u>-</u>
	Net cash flows from operating activities			4,140,610		1,402,518

(Continued)

<u>CHAROEN POKPHAND ENTERPRISE (TAIWAN) CO., LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS YEARS ENDED DECEMBER 31, 2023 AND 2022</u>

(Expressed in thousands of New Taiwan dollars)

(Expressed in the	isands of New 1a		Year ended Dec	ember 31
	Notes		2023	2022
CASH FLOWS FROM INVESTING ACTIVITIES				
Acquisition of financial assets at fair value through				
other comprehensive income		(\$	474,837) \$	_
Acquisition of property, plant and equipment	6(30)	(2,459,906) (2,255,295)
Proceeds from disposal of property, plant and	- ()		,, , (,, ,
equipment			74,971	11,245
Acquisition of intangible assets	6(10)	(49,639) (1,151)
Increase in other non-current assets	,	Ì	28,046) (18,803)
Cash receipt of interest		`	2,741	711
Cash receipt of dividends	6(3)(22)		37,118	66,108
Net cash flows used in investing activities		(2,897,598) (2,197,185)
CASH FLOWS FROM FINANCING ACTIVITIES		`		
(Decrease) increase in short-term borrowings		(704,056)	964,066
Increase (decrease) in short-term notes and bills		·	ŕ	
payable			40,187 (51,240)
Proceeds from long-term borrowings			11,330,000	8,758,510
Payment of long-term borrowings		(10,631,016) (7,784,750)
Payment of lease liabilities	6(9)	(66,463) (54,840)
Cash payment for interest		(208,371) (143,856)
Cash dividends paid	6(18)	(1,031,765) (803,973)
Cash receipt from non-controlling interest of a				
subsidiary through capital increase			10,000	49,000
Cash dividends paid to non-controlling interest		(21,047) (17,628)
Capital surplus - dividends not received by				
shareholders			-	1,974
Capital surplus - dividends not received by				
shareholders and others			3,894	<u>-</u>
Net cash flows (used in) from financing				
activities		(1,278,637)	917,263
Effects of changes in foreign exchange rate			125	1,481
Net (decrease) increase in cash and cash equivalents		(35,500)	124,077
Cash and cash equivalents at beginning of year	6(1)		311,085	187,008
Cash and cash equivalents at end of year	6(1)	\$	275,585	311,085

CHAROEN POKPHAND ENTERPRISE (TAIWAN) CO., LTD.

Table of Distribution of Surplus Earnings Year 2023

Unit: NTD

Items	Amo	ount
2023 Beginning retained earnings		2,522,844,625
Add: 2023 net profit after tax	2,268,964,355	
Add: Adjustment to 2023 retained earnings	(5,006,149)	
2023 net profit after tax and retained earnings adjustment		2,263,958,206
Less: 10% legal reserve		(226,395,821)
Distributable surplus earnings		4,560,407,010
Distributable items:		
Cash dividend to shareholders (NT\$ 5.5 per share)		1,621,345,539
Un-appropriated retained earnings after distribution		2,939,061,471

Chairman: Wu Yeh, Cheng CEO: Thong Chotirat Chief Accountant: Su Hua Lee

Appendix

CHAROEN POKPHAND ENTERPRISE (TAIWAN) CO., LTD.

Rules of Procedure for Shareholders Meetings

Approved by the General Shareholders' Meeting on June 18, 2002

- 1. Shareholders' Meeting of the Company (the "Meeting") shall be conducted in accordance with the Rules of Procedure, except as otherwise provided by the relevant laws and regulations.
- The Company shall furnish the attending shareholders with an attendance book to sign, or attending shareholders may hand in a sign-in card in lieu of signing in.
 The number of shares in attendance shall be calculated according to the shares indicated by the attendance book and sign-in cards handed in.
- 3. Attendance and voting at the Meeting shall be calculated based on the number of shares.
- 4. The venue for a shareholders meeting shall be the premises of the Company, or a place easily accessible to shareholders and suitable for a shareholders meeting. The meeting may begin no earlier than 9 a.m. and no later than 3 p.m.
- 5. If a shareholders meeting is convened by the Board of Directors, the meeting shall be chaired by the chairman of the Board. When the chairman of the Board is on leave or for any reason unable to exercise the powers of the chairman, the chairman shall appoint one of the directors to act as chair. Where the chairman does not make such a designation, the directors shall select from among themselves one person to serve as chair.

 If a shareholders meeting is convened by a party with power to convene but other than the Board of Directors, the convening party shall chair the meeting.
- 6. The Company may appoint its attorneys, certified public accountants, or related persons to attend a shareholders meeting. Persons handling administrative affairs of a shareholders meeting shall wear identification cards or arm bands.
- 7. The Company shall make an uninterrupted audio and video recording for the whole process of the Meeting. The recorded materials shall be retained for at least one year.
- 8. The chairman shall call the meeting to order at the appointed meeting time. However, when the attending shareholders do not represent a majority of the total number of issued shares, the chairman may announce a postponement, provided that no more than two such postponements, for a combined total of no more than 1 hour, may be made. If the quorum is not met after two postponements, but the attending shareholders represent one third or more of the total number of issued shares, a tentative resolution may be adopted pursuant to Article 175, paragraph 1 of the Company Act.

 When, prior to conclusion of the meeting, the attending shareholders represent a majority of the total number of issued shares, the chairman may resubmit the tentative resolution for a
- 9. If a shareholders meeting is convened by the Board of Directors, the meeting agenda shall be set by the Board of Directors. The meeting shall proceed in the order set by the agenda, which may not be changed without a resolution of the shareholders meeting.

vote by the shareholders meeting pursuant to Article 174 of the Company Act.

- The provisions of the preceding paragraph apply mutatis mutandis to a shareholders meeting convened by a party with the power to convene that is not the Board of Directors. The chairman may not declare the meeting adjourned prior to completion of deliberation on the meeting agenda of the preceding two paragraphs (including extraordinary motions), except by a resolution of the shareholders meeting.
- The shareholders cannot designate any other person as chairman and continue the Meeting in the same or other place after the Meeting is adjourned. In the event that the chairman declares the meeting adjourned in violation of the Rules of Procedure, the attending

- shareholders may elect a new chairman by agreement of a majority of the votes represented by the attending shareholders, and then continue the meeting.
- 10. Before speaking, an attending shareholder must specify on a speaker's slip the subject of the speech, his/her shareholder account number (or attendance card number), and account name. The order in which shareholders speak will be set by the chairman.
 - A shareholder in attendance who has submitted a speaker's slip but does not actually speak shall be deemed to have not spoken. When the content of the speech does not correspond to the subject given on the speaker's slip, the spoken content shall prevail.
 - When an attending shareholder is speaking, other shareholders may not speak or interrupt unless they have sought and obtained the consent of the chairman and the shareholder that has the floor; the chairman shall stop any violation.
- 11. Except with the consent of the chairman, a shareholder may not speak more than twice on the same proposal, and a single speech may not exceed 5 minutes. If the shareholder's speech violates the rules or exceeds the scope of the agenda item, the chairman may terminate the speech.
- 12. When a juristic person is appointed to attend as proxy, it may designate only one person to represent it in the Meeting.
 - When a juristic person shareholder appoints two or more representatives to attend a shareholders meeting, only one of the representatives so appointed may speak on the same proposal.
- 13. After an attending shareholder has spoken, the chairman may respond in person or direct relevant personnel to respond.
- 14. When the chairman is of the opinion that a proposal has been discussed sufficiently to put it to a vote, the chairman may announce the discussion closed and call for a vote.
- 15. Vote monitoring and counting personnel for the voting on a proposal shall be appointed by the chairman, provided that all monitoring personnel shall be shareholders of the Company. The results of the voting shall be announced on-site at the meeting, and a record made of the vote.
- 16. When a meeting is in progress, the chairman may announce a break based on time considerations.
- 17. Except as otherwise provided in the Company Act and in the Company's Articles of Incorporation, the passage of a proposal shall require an affirmative vote of a majority of the voting rights represented by the attending shareholders.
 - The resolution shall be deemed adopted and shall have the same effect as if it was voted by casting ballots if no objection is voiced after solicitation by the chairman.
- 18. When there is an amendment or an alternative to a proposal, the chairman shall present the amended or alternative proposal together with the original proposal and decide the order in which they will be put to a vote. When any one among them is passed, the other proposals will then be deemed rejection, and no further voting shall be required.
- 19. The chairman may direct the proctors or security personnel to help maintain order at the meeting place. When proctors or security personnel help maintain order at the meeting place, they shall wear an identification card or armband bearing the word "Proctor."
- 20. The Rules of Procedure and any amendments shall be implemented after adoption by shareholders meetings.

CHAROEN POKPHAND ENTERPRISE (TAIWAN) CO., LTD. Articles of Incorporation

Approved by the General Shareholders' Meeting on June 23, 2022

Chapter I- General Provisions

Article 1

The Company is incorporated, as a company limited by shares, under the Company Act of the Republic of China. The Company's Chinese name is 台灣卜蜂企業股份有限公司 and its English name is CHAROEN POKPHAND ENTERPRISE (TAIWAN) CO., LTD.

Article 2

The scope of business of the Company is as follows:

The sco	•	of the Company is as follows:
1	A401010	Operation of Livestock Farm
2	A401020	Animal Husbandry
3	A401040	Livestock Farming
4	C101010	Slaughter
5	C103050	Canned, Frozen, Dehydrated Food Manufacturing
6	C199030	Instant Food Manufacturing
7	C199990	Other Food Manufacturing Not Elsewhere Classified
8	C201010	Prepared Animal Feeds Manufacturing
9	F101040	Wholesale of Animal Husbandry
10	F101050	Wholesale of Aquatic Products
11	F102170	Wholesale of Food and Grocery
12	F103010	Wholesale of Animal Feeds
13	F201020	Retail sale of Husbandry Products
14	F201030	Retail Sale of Aquatic Products
15	F202010	Retail Sale of Animal Feeds
16	F203010	Retail Sale of Food and Grocery
17	F401010	International Trade
18	I101070	Agriculture, Forestry, Fishing and Animal Husbandry Consultancy
19	I101090	Food Consultancy
20	I103060	Management Consulting Services
21	IG01010	Biotechnology Services
22	F501060	Restaurants
23	F501990	Other Eating and Drinking Places Not Elsewhere Classified
24	C105010	Edible Oil and Fat Manufacturing
25	F102020	Wholesale of Edible Fat and Oil
26	F101130	Wholesale of Vegetables and Fruits
27	F101990	Wholesale of Other Agricultural, Livestock and Aquatic Poducts
28	F121010	Wholesale of Food Additives
29	F201010	Retail Sale of Agricultural Products
30	F201990	Retail Sale of Other Agricultural, Livestock and Aquaculture Products
31	F221010	Retail of Food Additives
32	F301020	Supermarkets
33	F399010	Convenience Stores
34	F399040	Retail Sale No Storefront
35	ZZ99999	All business items that are not prohibited or restricted by law, except those that are subject to special approval.

Article 2-1

The total amount of the Company's investment in other business shall be without the restriction of forty percent (40%) of the Company's paid-in capital.

Article 3

The Company has its head office in Taipei City. When it is necessary and with a resolution by the Board of Directors, the Company may set up branch offices and plants domestically and abroad.

Article 4

The Company may provide endorsements and guarantees to its subsidiaries or a company related to its business.

Chapter II - Shares

Article 5

The authorized capital of the Company is 3,579,000,000 New Taiwan Dollars, divided into 357,900,000 shares with a par value of ten New Taiwan Dollars (NT\$10) per share. All the shares may be issued in installments with a resolution by the Board of Directors.

Article 6

The share certificates of the Company shall be affixed with the signatures or personal seals of the director representing the company, serially numbered, indicated the particulars in accordance with Article 162 of the Company Act and shall be duly certified or authenticated by the bank which is competent to certify shares under the laws before issuance.

Article 6-1

When issuing new shares, the Company may print a share certificate in respect of the full number of shares to be issued at that time, and arrange for the share certificate to be kept by a centralized securities depositary enterprise.

The Company may be exempted from printing any share certificates for the shares issued, and the company shall register the issued shares with a centralized securities depositary enterprise.

Article 7

The transfer of shares, pledge of rights, loss, succession, gift, loss of seal, amendment of seal, change of address or similar stock affairs conducted by shareholders of the Company, shall follow the Regulations Governing the Administration of Shareholder Services of Public Companies promulgated by the competent authority, unless otherwise provided in laws and securities regulations.

Article 8

(Deleted)

Article 9

The alteration in the shareholders' roster shall be suspended within sixty (60) days prior to the date of a general shareholder's meeting, thirty (30) days prior to the date of a special shareholders' meeting, or five (5) days prior to the target date fixed by the Company for distribution of dividends, bonuses, or other benefits.

Article 10

Shareholders shall submit the seal specimen to the Company. The Company shall verify the seal used by a shareholder for claiming dividends or written exercising rights in compliance with seal specimen kept in the Company.

Chapter III- Shareholders' Meetings

Article 11

There are two kinds of shareholders' meetings, the general meetings and the special meetings.

- 1. General meetings shall be convened by the Board of Directors within six (6) months after the close of each fiscal year.
- 2. Special meetings shall be convened when necessary in accordance with the laws and regulations.

When the Company holds a shareholders' meeting, the meeting can be held by means of visual communication network, or other methods promulgated by the central competent authority.

Article 12

Unless otherwise provided in the Company Act, the Chairman of Board of Directors shall preside at each meeting of shareholders. In case that the Chairman is on leave or absence or cannot exercise his power and authority for any cause, the Chairman of Board of Directors shall designate either the Vice Chairman or one of the directors to act on his behalf in accordance with the Company Act. The shareholders' meeting shall be conducted in accordance with the Rules and Procedures of Shareholders' Meeting of the Company.

Article 13

A notice to convene a general meeting of shareholders shall be given to each shareholder no later than thirty (30) days prior to the scheduled meeting date. A notice to convene a special meeting of shareholders shall be given to each shareholder no later than fifteen (15) days prior to the scheduled meeting date. The date, place of the meeting and the causes or subjects of a shareholders' meeting to be convened shall be indicated in the individual notice to be given to shareholders.

Article 14

Unless otherwise provided in the Company Act, resolutions at a shareholders' meeting shall be adopted by a majority vote of the shareholders present, who represent more than one-half of the total number of voting shares.

Article 15

Except in the circumstances otherwise provided in laws and regulations, a shareholder shall have one voting power in respect of each share in his/her/its possession.

Article 16

If a shareholder is unable to attend a shareholders' meeting, he/she/it may appoint a proxy to attend a shareholders' meeting in his/her/its behalf by executing a power of attorney form printed by the Company and stating the scope of power authorized to the proxy.

The proxies to be used for attendance at a shareholders' meeting, unless otherwise provided in the Company Act, shall be in accordance with the Regulations Governing the Use of Proxies for Attendance at Shareholders' Meetings of Public Companies promulgated by the competent authority.

Article 17

Resolutions adopted at a shareholders' meeting shall be recorded in the minutes of the meeting, which shall be affixed with the signature or seal of the Chairman of the meeting and shall be distributed to all shareholders of the company within twenty (20) days after the close of the shareholders' meeting in accordance with the Company Act.

The minutes of shareholders' meeting shall record the date and place of the meeting, the name of the chairman, the method of adopting resolutions, and a summary of the essential points of the proceedings and the results of the meeting. The minutes shall be kept persistently throughout the life of the Company. The attendance list bearing the signatures of shareholders present at the meeting and the powers of attorney of the proxies shall be kept by the Company for a minimum period of at least one year.

However, if a lawsuit has been instituted by any shareholder in accordance with the provisions of Article 189 of the Company Act, the minutes of the shareholders' meeting involved shall be kept by the Company until the legal proceedings of the foregoing lawsuit have been concluded.

Chapter IV - Directors and Managerial Personnel

Article 18

There are eight directors of the Company, who shall be elected by the shareholders' meeting from among the persons with disposing capacity. The term of office of a director shall be three years, and a director may be eligible for re-election. The independent directors shall not be less than three in number and not less than one-fifth of the total number of directors. The election of directors is adopted by candidate nomination system. The election of independent directors and non-independent directors shall be held together, and the elected members of independent directors and non-independent directors shall be calculated separately.

The percentage of shareholdings of all directors shall be in accordance with the Rules and Review Procedures for Director and Supervisor Share Ownership Ratios at Public Companies promulgated by the competent authority.

Article 19

The Board of Directors is composed of the entirety of directors, in conducting business, shall act in accordance with laws and ordinances, the Articles of Incorporation, and the resolutions adopted at the

meetings of shareholders.

Article 20

The Company has a Chairman and may have a Vice Chairman; the Board of Directors shall elect a Chairman and/or a Vice Chairman from among the directors in accordance with the Company Act. The Chairman shall externally represent the Company.

Article 21

Meetings of the Board of Directors, unless otherwise provided for in the Company Act, shall be convened by the Chairman of the Board of Directors.

Unless otherwise provided for in the Company Act, or other laws and ordinances, resolutions of the Board of Directors shall be adopted by a majority of the directors at a meeting attended by a majority of the directors.

Article 22

The Chairman of Board Directors shall preside at the meetings of Board of Directors. In case that the Chairman is on leave or absence or cannot exercise his power and authority for any cause, the Chairman of Board of Directors shall designate either the Vice Chairman or one of the directors to act on his behalf in accordance with the Company Act. In case that a director cannot attend the meeting for any cause whatsoever, he/she may appoint another director to attend a meeting of the Board of Directors in his/her behalf.

In case a meeting of the Board of Directors is proceeded via visual communication network, then the directors taking part in such a visual communication meeting shall be deemed to have attended the meeting in person.

In the case of emergency, the meeting of the Board of Directors may be convened at any time. A notice for calling a meeting of the Board of Directors may be effected by means of written, electronic transmission or facsimile.

Article 23

The Company establishes an Audit Committee in compliance with Articles 14-4 of the Securities and Exchange Act. The Audit Committee and its independent director members shall exercise the power and authority in accordance with the provisions regarding supervisors in the Company Act, the Securities and Exchange Act, other laws and regulations.

Article 24 (Deleted)

Article 25

The Company has one Chief Executive Officer (CEO). The CEO is empowered by the Board of Directors, responsible for the business and employee recruit.

Article 26

Appointment and discharge of the CEO shall be nominated by the Chairman and be decided in accordance with the resolution of the Board of Directors.

Chapter V – Accounting

Article 27

The Company's fiscal year is starting from January 1 until December 31 of every calendar year. The final account closing shall be conducted at end of every fiscal year.

Article 28

After the final account closing of every fiscal year, the Board of Directors, in accordance with the Company Act, shall submit the following reports and statements to a general meeting of shareholders for ratification:

- 1. Business report;
- 2. Financial statements;
- 3. Surplus earning distribution or loss off-setting proposals.

Article 29

The Company is in the stage of stable growth, considering the capital demand of the Company and the cash inflow that the shareholders desire, while the Company has profit as a result of the annual final accounting, shall pay all taxes and dues pursuant to laws, offset its accumulated losses, and then set aside 10% of such profits as legal reserve. Where such legal reserve amount has reached the Company's paid-in capital, this provision shall not apply. The Company then set aside or reverse special reserve in accordance with the laws and regulations requested by the competent authority. The remaining surplus profits together with the un-

appropriated retained earnings of the previous years shall be distributed as shareholders' dividends proposed by the Board of Directors. Cash dividends shall not be less than 10% of the total distributed dividends. While the cash dividends per share is less than NT\$0.1, the cash dividends shall be distributed in the form of stock dividends.

The distributable dividends and bonuses, or the legal reserve and capital reserve provided in the Paragraph 1 of Article 241 of the Company Act, in whole or in part, may be paid in cash after a resolution has been adopted by a majority vote at a meeting of the Board of Directors attended by two-thirds of the total number of directors of the Company; and in addition thereto a report of such distribution shall be submitted to the shareholders' meeting. In the case of distribution in the form of new issued shares, shall be conducted by a resolution adopted at a shareholders' meeting.

Article 29-1

When the Company has profit of the current year, at least 1% or more shall be distributed as employees' bonuses. In case that the Company has accumulative losses, a sufficient amount shall be reserved to offset its accumulative losses in advance.

Article 30 (Deleted)

Article 31

The remuneration for the chairman and directors is according to the individual merit for the degree of participation and contribution in the operation of the Company, in view of the standards of international and local industry, the Board of Directors is authorized to determine the aforesaid remuneration. In case that a shareholder or a director acts as a managerial officer or staff/employee of the Company, he/she shall be deemed as a general staff/employee and be paid for the salary.

Chapter VI - Supplementation

Article 32

The organizational rules and the detailed procedures of business operation of the Company shall be separately determined by the Board of Directors.

Article 33

Any matters not provided for in these Articles of Incorporation shall be governed by the Company Act.

Article 34 (Deleted)

Article 35

These Articles of Incorporation were stipulated on July 30, 1977. The first Amendment was made on August 20, 1978, the second Amendment on June 10, 1979, the third Amendment on September 30, 1980, the fourth Amendment on December 31, 1980, the fifth Amendment on March 6, 1981, the sixth Amendment on June 10, 1981, the seventh Amendment on June 30, 1981, the eighth Amendment on May 29, 1982, the ninth Amendment on March 15, 1983, the tenth Amendment on May 2, 1984, the eleventh Amendment on September 30, 1984, the twelfth Amendment on May 28, 1985, the thirteenth Amendment on November 17, 1986, the fourteenth Amendment on July 29, 1987, the fifteenth Amendment on December 8, 1987, the sixteenth Amendment on April 1, 1988, the seventeenth Amendment on September 24, 1988, the eighteenth Amendment on April 17, 1989, the nineteenth Amendment on June 11, 1990, the twentieth Amendment on May 17, 1991, the twenty-first Amendment on June 4, 1992, the twenty-second Amendment on June 8, 1993, the twenty-third Amendment on May 23, 1994, the twenty-fourth Amendment on June 13, 1995, the twentyfifth Amendment on June 5, 1996, the twenty-sixth Amendment on May 28, 1997, the twenty-seventh Amendment on June 5, 1998, the twenty-eighth Amendment on May 26, 2000, the twenty-ninth Amendment on June 18, 2002, the thirtieth Amendment on June 14, 2005, the thirty-first Amendment on June 20, 2006, the thirty-second Amendment on June 28, 2007, the thirty-third Amendment on June 18, 2010, the thirtyfourth Amendment on June 21, 2012, the thirty-fifth Amendment on June 19, 2014, the thirty-sixth Amendment on June 17, 2015, the thirty-seventh Amendment on June 17, 2016, the thirty-eighth Amendment on June 15, 2017, the thirty-ninth Amendment on June 26, 2019, the fortieth Amendment on June 23, 2022. Any amendment to the Articles of Incorporation of the Company shall be in accordance with the resolution adopted at a shareholders' meeting, and be submitted to the competent authority.

CHAROEN POKPHAND ENTERPRISE (TAIWAN) CO., LTD.

Shareholding of All Directors

List of Directors Record Date: April 27, 2024

				Share	cholding While	e Elected	Elected Curr		olding				
Position	Name	:	Date Elected	Type	Shares	Shareholding Ratio%	Туре	Shares	Shareholding Ratio%	Remarks			
Chairman	Wu Yeh, Cheng	Penracentativas											
Director	Prasert Poongkumarn	of Charoen	of Charoen Pokphand Foods Public Company	of Charoen Pokphand Foods Public Company	Pokphand Foods Public Company				18.38%	Common Shares	83,676,832	28.39%	
Director	Chu Hsiung, Lin					June 15, 2023	Common Shares	54,193,826					
Director	Thong Chotirat												
Director	Monchai Leelaharat												
Independent Director	Yen Sung, Li		June 15, 2023	Common Shares	0	0.00%	Common Shares	0	0.00%				
Independent Director	Tsu M. Ongg		June 15, 2023	Common Shares	0	0.00%	Common Shares	0	0.00%				
Independent Director	nt Director Jin-Shong Yang		June 15, 2023	Common Shares	0	0.00%	Common Shares	0	0.00%				
		54,193,826			83,676,832								

Total issued shares on June 15, 2023: 294,790,098 Shares Total issued shares on April 27, 2024: 294,790,098 Shares

Note: The minimum required combined shareholding of all directors by law: 12,000,000 shares

The combined shareholding of all directors on April 27, 2024: 83,676,832 shares

CPE has established Audit Committee that minimum required combined shareholding of all supervisors by law is not applicable.